Skip to main content
PLOS ONE logoLink to PLOS ONE
. 2022 May 12;17(5):e0268057. doi: 10.1371/journal.pone.0268057

Exposure factors associated with SARS-CoV-2 seroprevalence during the first eight months of the COVID-19 pandemic in the Netherlands: A cross-sectional study

Demi M E Pagen 1,2,*, Stephanie Brinkhues 1,2, Nicole H T M Dukers-Muijrers 1,3, Casper D J den Heijer 1,2, Noortje Bouwmeester-Vincken 4, Daniëlle A T Hanssen 5, Inge H M van Loo 5, Paul H M Savelkoul 5,6, Christian J P A Hoebe 1,2,5
Editor: Ray Borrow7
PMCID: PMC9097988  PMID: 35551285

Abstract

Background

The availability of valid Severe Acute Respiratory Syndrome Coronvirus-2 (SARS-CoV-2) serological tests overcome the problem of underestimated cumulative Coronavirus Disease 2019 (COVID-19) cases during the first months of the pandemic in The Netherlands. The possibility to reliably determine the number of truly infected persons, enabled us to study initial drivers for exposure risk in the absence of routine testing. Numerous activities or circumstances can accelerate virus spread, here defined as exposure factors. Hence, we aimed to evaluate a wide variety of demographic, behavioural and social exposure factors associated with seropositivity during the first eight months of the pandemic in Limburg, The Netherlands.

Methods

SARS-CoV-2 point-seroprevalence was determined cross-sectionally to indicate previous infection in a convenience sample of minimal 10,000 inhabitants of the study province. All adult (18+ years) inhabitants of the study province were eligible to register themselves for participation. Once the initial 10,000 registrations were reached, a reserve list was kept to ensure sufficient participants. Possible exposure factors were mapped by means of an extensive questionnaire. Associated exposure factors were determined using univariable and multivariable logistic regression models.

Results

Seropositivity was established in 19.5% (n = 1,948) of the 10,001 participants (on average 49 years old (SD = 15; range 18–90 years), majority women (n = 5,829; 58.3%). Exposure factors associated with seropositivity included current education, working in healthcare and not working from home, and being a member of three or four associations or clubs. Specifically for February-March 2020, visiting an après-ski bar during winter sports in Austria, travelling to Spain, celebrating carnival, and participating in a singing activity or ball sport were associated with seropositivity.

Conclusions

Our results confirm that relevant COVID-19 exposure factors generally reflected circumstances where social distancing was impossible, and the number and duration of contacts was high, in particular for indoor activities.

Introduction

By November 2021, there have been more than 246 million confirmed coronavirus disease 2019 (COVID-19) cases worldwide since the start of the pandemic, accompanied by approximately 5 million COVID-related reported deaths [1]. On 27th February 2020, the first COVID-19 case was confirmed in the Netherlands [2]. Initially, the province of Limburg was one of the most heavily affected Dutch provinces, with 439 confirmed cases per 100,000 inhabitants until July 2020 and the highest hospitalization and mortality rate nationally [3]. Average mortality was exceeded with 62% for this province during the first nine weeks of the pandemic [4]. Burden continued during the second wave of infections, when the southern provinces remained the most affected areas regarding COVID-related deaths as well [3]. Over time, new virus variants emerged, maintaining new waves of infections. These new variants display alternations in transmissibility and infectivity [5], and thereby continuously put pressure on defining the most effective infection prevention measures to combat the exponential growth of new COVID-19 cases.

In the Netherlands, the total number of COVID-19 cases was largely underestimated during the first months of the pandemic. Patients were initially only tested for COVID-19 when clinical symptoms were present (i.e. fever (≥ 38°C) and dyspnoea and/or cough) together with an epidemiological link (i.e. contact with a confirmed case or travel to an high COVID-19 incidence area) [6]. This underestimation limited the possibility to assess which factors contributed to the primary spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

Numerous activities or circumstances can accelerate virus spread, here defined as exposure factors. Since SARS-CoV-2 can be transmitted directly and by air, social distancing with a minimum of one to two meters is assumed to be sufficient to avoid spreading [7]. Furthermore, air quality and adequate ventilation is key, as shown in an experimental setting where SARS-CoV-2 remained viable in aerosols for the duration of three hours [8]. The application of social distancing and ventilation measures are unequally spread over settings and contexts, such as types of occupation. A significantly increased risk of COVID-19 infection was established among frontline healthcare workers in the United Kingdom [9]. A Norwegian population-based study showed that other healthcare workers (e.g. nurses, physicians, dentists and physiotherapists), people working in hospitality industry and in (public) transport also had a higher odds of a COVID-19 infection confirmed by positive polymerase chain reaction (PCR) during the first two waves of infection [10]. Just before infection prevention measures were implemented in March 2020, many mass events such as the annual carnival celebrations took place (Fig 1). Subsequent interdiction of mass events by the implemented measures, challenged the opportunity to measure their contribution to virus spreading at later times.

Fig 1. Timeline depicting events, first COVID-19 case, implementation of prevention measures and cumulative confirmed COVID-19 cases.

Fig 1

To better understand initial drivers for exposure risk in the absence of routine testing at that time, serology can be used to identify (unnoticed) infections. Defining the first–untested and therefore unconfirmed–COVID-19 cases is essential, as implementation of infection prevention measures largely eliminated exposure factors which were abundant in the first period. Serological testing in an unvaccinated population allows to reliably determine the number of truly infected persons. In 92% of the cases, COVID-19 antibodies are still detectable seven months after infection [11]. Hence, our study aimed to evaluate seroprevalence exposure factors associated with seropositivity during the first eight months of the pandemic, assessed prior to vaccination. Determining these exposure factors that facilitate transmission can be useful to inform future infection prevention policies and potentially confirm the effectiveness of existing measures.

Method

Study design

A cross-sectional study was designed to assess exposure factors which contributed to the spread of SARS-CoV-2 in the first eight months of the pandemic. A convenience sample of 10,000 inhabitants of a southern Dutch province was used, reflecting about 1% of 1 million adults in this province. Point-seroprevalence was determined to indicate previous infection. Possible exposure factors were mapped by means of an extensive questionnaire. A convenience sample was chosen to accommodate equal opportunities for the general population in their great demand on to know about their COVID-19 serostatus.

Participants

All adult inhabitants of 18 years and older of our study province (Limburg) were eligible for participation until sufficient registrations were reached. After the first 10,000 registrations were reached, registrations were automatically allocated to the reserve list. When initial registered participants declined participation, adults registered on the reserve list were invited (first-come-first-serve) to ensure sufficient participants (minimally 10,000). Participants needed to speak, read, and write Dutch language, as the questionnaire was only available in Dutch. This applies to 95% of our study province inhabitants [12].

Data collection

Data collection was completed between 28th October and 23rd December 2020 and comprised donating a blood sample and filling out an online questionnaire.

Online participation registration was conducted via market research software from Crowdtech (ISO-20252 and ISO-27001 certified, London, UK). To register, personal and contact details were required. An appointment for blood drawing was made by phone at one of the four test locations (Maastricht, Urmond, Landgraaf, and Venlo). One 10 ml ethylenediaminetetraacetic acid (EDTA) tube was taken by venepuncture by trained and certified health professionals. All blood samples were kept at room temperature and transported to the Medical Microbiology Laboratory of the Maastricht University Medical Centre+ (MUMC+). Samples were tested for total COVID-19 antibodies using the Wantai SARS-CoV-2 Ab enzyme-linked immunoassay (ELISA) test (Beijing Wantai Biological Pharmacy Enterprise Co., Ltd., Beijing, China) in accordance with the manufacturer’s instructions [13]. This test was chosen after showing best performance in a multicentre evaluation by the National Institute for Health and Environment [14]. Samples were classified by optical density value as being positive, borderline, or negative. In our study, eight samples had borderline values. Based on pilot experience using the Wantai among five hospital employees with serum pairs, four out of five borderline values seroconverted to positive in a second serum sample. Therefore, we decided to classify the borderline values as positives. Participants were informed about their serostatus via email within three weeks after providing the blood sample.

Exposure measures

The online questionnaire was sent by email at least two days after providing the blood sample. The questionnaire covered: general demographics, current education, occupation and opportunity to work from home, memberships to associations or clubs, and specific behaviours performed during the first months (February-March 2020) of the pandemic.

Demographics included gender, age, place of residence and level of education. Level of education was categorized into practically trained (no, lower general, lower vocational, general secondary, and secondary vocational education) and theoretically trained (higher general, pre-university, higher professional, and scientific education). Based on place of residence, two geographical regions of the study province were established: northern and southern. A variety of occupations was listed, such as healthcare, education, day-care, and catering industry. Working in healthcare was further defined by specific sectors. The degree of working from home was determined for different time periods: February-March, April-May, and June-November 2020. Working from home was dichotomized into not working from home during all periods and (partly) working from home during at least one of the periods. Membership to a variety of associations or clubs was assessed and being member to a music association was further specified. Memberships to multiple associations or clubs with a perceived higher risk of infection were merged, including membership to a sport, youth, volunteer, social or traditional association of the study province and a fanfare, brass or jazz band were summed up. To grasp all singing activities together as an exposure factor we combined being member of a choral society, a (church)choir or participated in a singing activity. Specific behaviours performed in February-March 2020 comprised travelling for winter sports or other purposes, celebrating carnival, and attending specific activities. For travelling, country of destination was specified supplemented with extent to which participants visited an après-ski bar when travelled for winters sport (i.e., not, couple of days, or majority of the days). For all carnival days separately the amount of time spend inside was counted. A sum score was calculated for attending carnival celebrations inside for all carnival days combined. The score was divided in four categories based on quartiles. Eventually, involvement in 48 different activities where at least 30 people were present was counted. Activities were categorized in religious ceremonies, attractions, events, cultural activities, hobbies, sports, going out, and others. For nine activities the specific date and place of the activity were indicated (attending a wedding or funeral, visiting a museum, convention, charity event, festival, sport event, professional soccer match, or taking a day trip by bus or boat). A telephone helpline was available to facilitate assistance for participants who were unable to fill out the questionnaire themselves.

Statistical analysis

Only complete participation was taken into analysis, meaning participation with both a blood sample and questionnaire. No missing data had to be handled, since all questions in the questionnaire were mandatory.

Seroprevalence was a dichotomous outcome measure (positive or negative). Seroprevalence was used to identify possible exposure factors, meaning factors where proportion of seropositive participants exceeded the average. Univariable and corrected multivariable logistic regression analysis were used to study the association between possible exposure factors and seropositivity. Exposure factors with a p-value <0.05 in univariable logistic regression were retained in the multivariable model and multicollinearity between exposure factors was checked. Interactions between exposure factors and geographical region were tested. No geographical differences in exposure factors were established. A p-value of <0.05 was considered statistically significant. Data were analysed using Statistical Package for the Social Sciences (SPSS) (version 26.0, IBM, Armonk, USA).

Ethical statement

The study protocol, participant information form and written informed consent form were reviewed and approved by the Medical Ethical Committee of the MUMC+ (NL74791.068.20/METC20-071). The study is registered at the Netherlands Trial Register (NL8889).

Results

In total 10,108 participants provided a blood sample and 10,001 participants additionally completed the questionnaire, which was taken as the study population (Fig 2). Main reasons for declining participation included: changed their mind, did not show during appointment, unable to reach, and current COVID-19 infection.

Fig 2. Flow chart of total study population (n = 10,001) stratified for initial registrations and reserve registrations.

Fig 2

Study population versus source population

About 1% of the adult inhabitants of all 42 municipalities in the study province participated: ranging from 0.2% to 1.5% within the various municipalities. The age distribution of participants was comparable to the source population, but the study population included relatively more women; 58.3% versus 50.3% in the source population.

Sociodemographic characteristics of the study population

Participants were on average 49 years of age (standard deviation (SD): 15, range 18–90) and 52.3% of the participants were theoretically trained. A considerable number of participants worked in healthcare (Table 1). Some participants (n = 286) were aware of their prior COVID-19 infection, PCR confirmed.

Table 1. Characteristics of total study population (n = 10,001) and stratified for serostatus.

Total n = 10,001 Seronegative Seropositive
n = 8,053 n = 1,948
Gender SP (%) 95% CI n % n % N %
Male 18.7 17.5–19.9 4,167 41.7 3,389 42.1 778 39.9
Female 20.0 19.0–21.0 5,829 58.3 4,662 57.9 1,167 59.9
Other - 5 0 2 0 3 0.2
Age (mean (SD)) - 49 (15) 49 (15) 50 (15)
Age
18–29 years 22.8 20.4–25.1 1,208 12.1 933 11.6 275 14.1
30–39 years 16.5 14.7–18.2 1,676 16.8 1,400 17.4 276 14.2
40–49 years 16.9 15.2–18.7 1,766 17.7 1,467 18.2 299 15.3
50–59 years 21.0 19.4–22.7 2,393 23.9 1,890 23.5 503 25.8
60–69 years 20.3 18.6–22.0 2,163 21.6 1,723 21.4 440 20.3
70–79 years 19.4 16.6–22.3 746 7.5 601 7.5 145 7.4
80+ years 20.8 9.3–32.3 49 0.5 39 0.5 10 0.5
Geography
Northern part 23.6 22.7–24.4 3,770 37.7 2,882 35.8 888 45.6
Southern part 17.0 16.3–17.7 6,231 62.3 5,171 64.2 1,060 54.4
Level of education
Practically trained 20.6 19.5–21.8 4,768 47.7 3,784 47.0 984 50.5
Theoretically trained 18.4 17.4–19.4 5,233 52.3 4,269 53.0 964 49.5
Occupation
Healthcare 25.8 23.6–27.9 1,567 15.7 1,163 14.4 404 20.7
Catering industry 23.8 18.7–28.9 269 2.7 205 2.5 64 3.3
Non-medical service 22.1 15.5–28.6 154 1.5 120 1.5 34 1.7
Youth care 18.8 12.8–24.7 165 1.6 134 1.7 31 1.6
Education 18.5 15.5–21.5 644 6.4 525 6.5 119 6.1
Day-care 18.3 11.1–25.6 109 1.1 89 1.1 20 1.0
Retail 18.7 14.7–22.6 375 3.7 305 3.8 70 3.6
Other transport and storage 23.7 16.7–30.8 139 1.4 106 1.3 33 1.7
Administration 20.1 17.1–23.0 693 6.9 554 6.9 139 7.1
Knowledge work 16.3 13.8–18.8 830 8.3 695 8.6 135 6.9
Technical 19.1 16.4–21.8 801 8.0 648 8.0 153 7.9
Government 17.6 14.9–20.3 766 7.7 631 7.8 135 6.9
Emergency servicesa 10.4 5.3–15.6 134 1.3 120 1.5 14 0.7
Media and communication 11.9 7.5–16.3 210 2.1 185 2.3 25 1.3
Otherb 17.3 15.9–18.7 318 3.2 263 3.3 55 2.8
Not working 18.3 14.1–22.5 2,827 28.3 2,310 28.7 517 26.5
Type of healthcare facility
Disabled care 37.1 29.8–44.4 167 1.7 105 1.3 62 3.2
Home care 26.6 19.3–33.9 139 1.4 102 1.3 37 1.9
Nursing home 31.1 24.0–38.2 163 1.6 112 1.4 51 2.6
Hospital 26.5 20.8–32.2 234 2.3 172 2.1 62 3.2
Otherc 22.2 19.4–25.0 864 8.6 672 8.3 192 9.8
Not working in healthcare 18.3 17.5–19.1 8,434 84.3 6,890 85.6 1,544 79.3

Note.- CI, confidence intervals; SD, standard deviation; SP, seroprevalence.

a Excluding ambulance service.

b Process industry, agriculture and horticulture, public transport, transport of fuels and waste or other.

c Ambulance service, physiotherapy and occupational therapy, intramural and extramural mental healthcare, general practice, youth care, maternity care or obstetric practice, rehabilitation clinic, dental practice, small scale housing, residential care institution or other.

Values are n (%) unless otherwise specified. Seroprevalence represents the proportion of seropositive participants in the total study population. Percentages per category are presented for total study population, seronegative and seropositive populations.

Seroprevalence

Overall, 1,948 of the 10,001 participants tested positive for presence of COVID-19 antibodies (19.5% [95% Confidence Interval (CI):18.7%-20.3%]). Seroprevalence varied geographically and was higher in the northern part (23.5% [95% CI:22.2%-24.9%]) than the southern part (17.0% [95% CI:16.0%-17.9%]). A difference in seroprevalence was observed between men (18.7% [95% CI:17.5%-19.9%]) and women (20.7% [95% CI:19.0%-21.0%]). A relatively high seroprevalence was observed among participants aged between 18 and 29 years of age (22.8% [95% CI:20.4%-25.1%]) and practically trained participants (20.6% [95% CI:19.5%-21.8%]) (Table 1).

Exposure factors associated with seropositivity (Table 2)

Table 2. Exposure factors associated with SARS-CoV-2 seroprevalence stratified for univariable and multivariable logistic regression models.

Univariable Multivariable
Gender N SP (%) OR 95% CI p value OR 95% CI p value
Male (ref.) 4,167 18.7 - - 0.043 - - 0.064
Female 5,829 20.0 1.08 0.98–01.20 0.126 1.04 0.93–1.16 0.490
Other 5 - - - - - - -
Age (years) 10,001 - 1.00 1.00–1.00 0.748 1.01 1.00–1.01 <0.001
Current education
No (ref.) 9,309 19.1 - - 0.001 - - 0.008
Other/unknown education 140 17.1 0.88 0.56–1.36 0.555 0.92 0.58–1.45 0.718
Secondary school 39 28.2 1.66 0.83–3.34 0.155 1.93 0.94–3.96 0.074
Secondary vocational education 66 33.3 2.11 1.26–3.54 0.004 1.88 1.10–3.23 0.022
Higher professional education 232 23.3 1.28 0.94–1.75 0.114 1.27 0.91–1.78 0.165
Scientific education 215 26.5 1.53 1.12–2.07 0.007 1.60 1.14–2.25 0.007
Level of education
Practically trained (ref.) 4,768 20.6 - - - - - -
Theoretically trained 5,233 18.4 0.87 0.79–0.96 0.005 0.90 0.81–1.00 0.058
Geography
Southern part (ref.) 6,231 17.0 - - - - - -
Northern part 3,770 23.6 1.50 1.36–1.66 <0.001 1.44 1.30–1.60 <0.001
Work sector
Other (ref.) 8,165 18.1 - - <0.001 <0.001
Healthcare other—(partly) worked from home 500 19.0 1.06 0.84–1.33 0.623 1.21 0.96–1.54 0.113
Healthcare other—not worked form home 364 26.6 1.64 1.29–2.08 <0.001 1.72 1.34–2.20 <0.001
Disability care—(partly) worked from home 83 24.1 1.43 0.86–2.38 0.163 1.37 0.81–2.29 0.239
Disability care—not worked from home 84 50.0 4.52 2.93–6.95 <0.001 4.17 2.68–6.49 <0.001
Home care—(partly) worked from home 41 22.0 1.27 0.61–2.67 0.527 1.35 0.64–2.87 0.432
Home care—not worked from home 98 28.6 1.81 1.16–2.81 0.009 1.70 1.08–2.69 0.022
Nursing home care—(partly worked from home) 61 29.5 1.89 1.09–3.29 0.024 2.01 1.14–3.52 0.015
Nursing home care—not worked from home 102 32.4 2.16 1.42–3.28 <0.001 2.20 1.44–3.38 <0.001
Hospital care—(partly) worked from home 113 23.8 1.49 0.97–2.29 0.071 1.58 1.02–2.46 0.041
Hospital care—not worked from home 121 28.1 1.77 1.18–2.63 0.005 1.75 1.16–2.62 0.007
Catering—(partly) worked from home 182 23.6 1.40 0.99–1.98 0.059 1.34 0.93–1.91 0.112
Catering—not worked from home 87 24.1 1.44 0.88–2.36 0.150 1.47 0.89–2.44 0.133
Member association/club
No member (ref.) 5,182 17.8 - - <0.001  - 0.019
Member of one association/club 3,772 20.6 1.20 1.08–1.34 0.001 1.09 0.98–1.22 0.123
Member of two associations/clubs 925 22.6 1.35 1.14–1.60 <0.001 1.12 0.93–1.34 0.240
Member of three/four associations/clubs 122 33.6 2.35 1.60–3.44 <0.001 1.82 1.22–2.72 0.003
Winter sports and travelling abroad
No winter sports (ref.) 9,440 19.0 - - <0.001  - <0.001
No après-ski during winter sports Austria 163 20.2 1.08 0.73–1.59 0.697 1.22 0.83–1.81 0.313
A few days après-ski during winter sports Austria 158 22.2 1.21 0.83–1.77 0.324 1.26 0.85–1.86 0.246
Majority of the days après-ski during winter sports Austria 240 34.6 2.25 1.72–2.95 <0.001 2.49 1.88–3.29 <0.001
Travelled abroad to Spain 282 24.1 1.33 1.00–1.75 0.047 1.41 1.06–1.87 0.019
Celebrating carnival
Did not celebrate carnival (ref.) 4,725 17.9 - - <0.001  - 0.088
Celebrated less than or 3 hours inside 1,373 19.0 1.07 0.92–1.25 0.369 1.09 0.93–1.27 0.310
Celebrated between 3 and 8 hours inside 1,288 19.4 1.10 0.94–1.29 0.228 1.08 0.92–1.28 0.329
Celebrated between 8 and 18 hours inside 1,422 21.7 1.27 1.10–1.47 0.001 1.19 1.02–1.40 0.026
Celebrated more than 18 hours inside 1,193 23.5 1.40 1.20–1.63 <0.001 1.24 1.04–1.47 0.016
Specific activities February-March 2020
Singing activitiesa 389 28.8 1.71 1.37–2.15 <0.001 1.65 1.30–2.08 <0.001
Attended funeral 504 23.2 1.27 1.02–1.57 0.030 1.08 0.86–1.35 0.494
Played wind instrument in interplay 164 27.4 1.58 1.12–2.23 0.010 1.26 0.88–1.81 0.210
Visited sport event (except soccer game) 323 26.0 1.47 1.14–1.90 0.003 1.18 0.90–1.55 0.234
Practiced gymnastics 110 27.3 1.56 1.02–2.38 0.039 1.22 0.78–1.90 0.379
Practiced ball sports (except soccer) 174 36.2 2.39 1.75–3.27 <0.001 1.90 1.36–2.65 <0.001
Visited a bar or café 1,657 23.4 1.33 1.17–1.51 <0.001 1.13 0.96–1.32 0.145
Visited a club or disco 294 26.2 1.49 1.14–1.94 0.003 1.23 0.90–1.66 0.189
Went out for dinner 2,294 22.0 1.23 1.09–1.37 <0.001 1.03 0.89–1.19 0.691
Took a day trip with bus or boat 50 34.0 2.14 1.19–3.85 0.011 1.78 0.97–3.27 0.064
Constant 0.09   0.000

*P-values<0.05 are shown in bold.

Note.- CI, confidence intervals; OR, odds ratio; Ref., reference category; SARS-CoV-2, Severe Acute Respiratory Syndrome Coronavirus-2; SP, seroprevalence.

a Being member of a choral society, (church)choir or participating in singing activity in February-March 2020.

Multivariable logistic regression model is additionally corrected for age, gender, level of education and geographical region. Overall Cox R2 of the multivariate model was 0.032.

Participants following vocational secondary education or scientific education had an increased odds for testing seropositive (Odds Ratio (OR) = 1.88 [95% CI:1.10–3.23] and 1.60 [95% CI:1.14–2.25], respectively).

The odds of seropositivity was 1.55 [95% CI:1.37–1.76] for participants working in healthcare versus participants not working in healthcare. The odds were notably higher in disability care (OR = 4.17 [95% CI:2.68–6.49]). Overall, not working from home was associated with an increased odds in all healthcare sectors.

Participants being a member of three or four associations or clubs (listed in methods section) were more likely to have COVID-19 antibodies (OR = 1.82 [95% CI:1.22–2.72]. Singing activities also increased odds of seropositivity (OR = 1.65 [95% CI:1.30–2.08]).

Specific factors for February-March 2020

Visiting an après-ski bar for the majority of the days during winter sports in Austria was associated with increased odds for seropositivity (OR = 2.49 [95% CI:1.88–3.29]). In addition, traveling to Spain was established to be associated (OR = 1.41 [95% CI:1.06, 1.87]).

Carnival celebrations while spending more than eight hours inside was positively associated with seropositivity (OR between 8 and 18 hours = 1.19 [95% CI:1.02–1.40] and OR more than 18 hours = 1.24 [95% CI:1.04–1.47].

Of the various other activities evaluated, the following increased odds for seropositivity: attended a funeral, played a wind instrument in interplay, visited a sport event (except soccer game), practiced gymnastics, practiced a ball sport (except soccer), visited a bar, café, club, or disco, went out for dinner, and took a day trip by bus or boat.

Practicing a ball sport (except soccer) was associated with seropositivity in the multivariate model (OR = 1.90 [95% CI:1.36–2.65]).

Notable activities with insufficient participants

An exceptionally high seroprevalence appeared among the participants who attended a charity event in Kessel, a small village in the middle of the study province, which was more than four times the average seroprevalence. Only 15 participants attended this event, making this result sensitive to bias. Two other specific events, namely visiting professional soccer matches in Maastricht, resulted in seroprevalences up to twice the average. Likewise, the number of participants was too small for these events.

Discussion

In this cross-sectional study evaluating the seroprevalence and extensive questionnaire data from 10,000 inhabitants of a southern Dutch province, the seroprevalence was almost 20% by the end of 2020. Several exposure factors were independently associated with seropositivity: following secondary vocational or scientific education, working in healthcare and not working from home, and being a member of three or four associations or clubs. Specifically, for the months of February-March 2020, relevant exposure factors included visiting an après-ski bar in Austria for the majority of the days during winter sports, travelling to Spain, celebrating carnival for longer than eight hours inside, participating in a singing activity, and practicing a ball sport. The majority of the independently associated exposure factors established in our study reflect circumstances where social distancing is probably not generally maintained. Moreover, circumstances where participants are thought to have a high contact rate and activities performed inside show clear associations with seropositivity.

The fact that the initial strict Dutch testing policy greatly underestimated cumulative infections, is highlighted by the results of our study. Until 1st December 2020, in total 25,592 PCR confirmed COVID-19 cases were reported among 1.12 million inhabitants of the study province, reflecting 2.3% of all inhabitants [3]. The seroprevalence calculated in our study is almost ten times higher compared to the PCR confirmed COVID-19 cases since 27th February 2020 in the study province (2.3% versus 19.5%).

Other Dutch seroprevalence studies established seroprevalences between 11% and 12% in healthy plasma donors in November 2020, and between 5% and 10% in a representative sample of Dutch inhabitants in September 2020 [15, 16]. Overall, our study established the highest seroprevalence in the study province. However, it should be considered that due to the convenience sample, there is a possibility that people who expected to have had an COVID-19 infection were more likely to participate. This could result in a slight overestimation of the seroprevalence in our study.

The effect of not maintaining social distancing can be seen in occupational settings. Working in healthcare often requires direct patient contact which makes social distancing impossible. Several studies have identified an increased risk of COVID-19 infection in healthcare [9, 10, 16]. The possibility of encountering an infected patient is high among healthcare workers, as severely ill patients are admitted to healthcare facilities to receive required treatment [17].

In addition to the nature of a specific occupation itself, the possibility of working from home diminishes occupational exposure risk. A large Dutch cross-sectional population-based study supports this, by showing 0.71 times lower odds of seropositivity among participants working from home compared to participants not working from home, independent of work sector. The reason for the decreased risk may be partly the result of reduced daily physical contact with colleagues or clients. Seroprevalence was namely also 0.61 times lower among participants without physical contact with patients or clients in their professional or voluntary work [16].

Social distancing is closely related to the contact rate. A reduction of 71% in the average number of community contacts was observed, since social distancing measures were implemented in the Netherlands [18]. Circumstances where participants were thought to have a great contact rate showed a higher seroprevalence in our study, including being a member of three or four clubs or associations. Attending social meetings equals more varying social contacts, in turn increasing the possibility of getting in contact with a COVID-19 infected person. This is supported by a previous study examining the association between network parameters and several self-reported infections [19]. Among 3,004 Dutch participants aged 60 years on average, network size was significantly associated with upper respiratory tract and gastrointestinal infection. For every additional 10% of acquaintance contacts, including club mates, the odds of lower respiratory tract infection increased by 4%. However, this study did not show a significant association between number of club memberships and any of the above-mentioned infections.

The probability of virus transmission in a contact is partly determined by the stability of the virus in the environment, which is greater in circumstances with insufficient ventilation. Spending time inside, for example celebrating carnival or going to an après-ski bar during winter sports, shows a clear association with seropositivity in our study. One comparable study regarding spending time inside was carried out among 1,120 Danish medical students. Students who attended one or two parties organized before lockdown happened demonstrated a sixfold increase of seropositivity [20]. These findings highlight that an indoor environment is favourable for SARS-CoV-2 transmission. Nevertheless, no significant association was established between visiting a regular bar, café, or disco and seropositivity in our study. This might be explained by the large proportion of participants that undertook this type of activity, leading to an approximate even distribution between seropositive and seronegative participants. As this activity is not very specific, the association might be faded by other more pronounced activities and circumstances. Moreover, the counted visits to a bar, café, or disco not related to the carnival celebrations were in all probability before COVID-19 was widely spread in the study province. Therefore, there is a lower chance of getting infected during this kind of visit. Subsequently, implementation of infection prevention measures totally prohibited visiting these facilities, thereby eliminating exposure risk in this setting.

Furthermore, the impact of effortless travel nowadays should not be underestimated. According to an American mathematical modelling study, unconstrained mobility would have significantly accelerated the spread of SARS-CoV-2, especially in Central Europe, Spain and France [21]. The significant associations with travel destinations determined in our study support this.

The possible indirect impact of the COVID-19 pandemic on general health and lifestyle, for instance provoked by lockdowns, implementation of infection prevention measures and required self-isolation, has to be addressed. Increased alcohol consumption or intake of illegal substances–known to have a detrimental effect on health–have been shown during the second emergency state of the pandemic [22]. In contrast, the indirect impact of the pandemic could be effectively counteracted by stimulating the intake of a balanced diet, resulting in symbiosis by modulating the gut microbiota [23]. It is crucial to find the right balance between combatting waves of infection and thereby protecting public health on one side, and limiting the detrimental indirect effect of lockdowns and infection prevention measures on health on the other side.

To the best of our knowledge, this is the first large scale study examining an extensive diversity of possible demographic, social and behavioural risk factors for SARS-CoV-2 seropositivity. The questionnaire mapped many exposure factors and gave rise to the possibility to correct analyses for relevant characteristics. Regarding the validity of the serological test used in our study, a nationwide multicentre evaluation study indicated high sensitivity (97.5% after severe infection and 95.4% after mild infection) and high specificity of 99.6%, using PCR as reference [13]. Solely serology could be used to estimate cumulative infections, as initially a strict testing policy was maintained in the Netherlands. All tests were performed in the same laboratory, limiting differences in processing and execution of the tests, making results well comparable.

Our study had some limitations as well. First, selection bias cannot be ruled out due to the convenience sampling. However, sampling methods including a random sample can be subjected to substantial non-response, resulting in bias as well. The yielded study population in our study is quite representative regarding geographical and age distribution. Considering we were interested in exposure factors, the generalizability of the determined seroprevalence was less relevant. Second, recall bias could have occurred since participating in specific activities was listed for a period up to eight months earlier. Associations can be underestimated when participants did not remember their attendance at a specific event. In the study design, we attempted to limit recall bias by encouraging participants to use their agenda when filling out the questionnaire. Completing the questionnaire at home diminished time pressure and lowered possible recall bias as well. Third, associations between exposure factors at the beginning of the pandemic and seropositivity might be attenuated, due to the possible long period between the exposure and serology testing. Related to this, the overall multivariate model has a low R2 of 3.2%, meaning that a small part the variance in the data can be explained by the final model. This indicates that there are many more factors that contributed. From source and contact tracing activities we know that many infections occur, for instance, at home or during contacts with friends. Factors like cohabitation and the presence of children that go to school, but also general health before COVID-19, may predispose individuals to COVID-19 infection risk. In an eight-month period, there are innumerable activities and circumstances where an infection can be acquired. Nevertheless, exposure factors that took place before the official first COVID-19 cases, for example the carnival celebrations, were still independently associated, implying that these factors have substantially contributed to the primary spread of the virus.

In conclusion, the strict Dutch testing policy resulted in a great underestimation of cumulative COVID-19 infections during the first wave. Our results confirm that relevant COVID-19 exposure factors generally reflect circumstances where social distancing was impossible, and the number and duration of contacts was high, in particular for indoor activities (without proper ventilation). The measures taken at the beginning of the pandemic accurately targeted these circumstances to contain virus transmission. Confirmation of these prevention measures is of great value to take lessons from the initial response to the pandemic, and thereby provides guidance on steps to take in new waves of infection with new virus variants.

Moreover, our results can have an added value in responsibly relaxing infection prevention measures and reopening society, as they can help to prioritize which activities should be addressed as high COVID-19 risk. Subsequently, the risk of exponential spreading can be managed when allowing these ‘high risk’ activities again.

Acknowledgments

We gratefully acknowledge CJD Goense and LCJ Steijvers for their valuable contribution to the development of the questionnaire, and the technicians of the Department of Medical Microbiology subdivision serology of the MUMC+.

Data Availability

Data cannot be shared publicly because the data contains potentially identifying and sensitive participant information. Due to the General Data Protection Regulation, it is not allowed to distribute or share any personal data that can – directly or indirectly – be traced back to an individual. Besides, publicly sharing the data would not be in accordance with participants’ consent obtained for this study. Therefore, data are available from the head of the data-archiving of the Public Health Service South Limburg on reasonable request (Helen Sijstermans: helen.sijstermans@ggdzl.nl).

Funding Statement

This work was financially supported by the Province of Limburg, the Netherlands. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.WHO Coronavirus (COVID-19) Dashboard. Available at: https://covid19.who.int/. Accessed 3-11-2021.
  • 2.Alderweireld CEA, Buiting AGM, Murk J-LAN, Verweij JJ, Berrevoets MAH, van Kasteren MEE. COVID-19: patiënt nul in Nederland. Nederlandse tijdschrift voor geneeskunde 2020. [PubMed] [Google Scholar]
  • 3.Epidemiologische situatie COVID-19 in Nederland: Rijksinstituut voor Volksgezondheid en Milieu (RIVM), 2020.
  • 4.In welke provincie overleden meer mensen dan verwacht? Available at: https://www.cbs.nl/nl-nl/faq/corona/regionaal/in-welke-provincie-overleden-meer-mensen-dan-verwacht-. Accessed 8 July 2021.
  • 5.Thakur V, Bhola S, Thakur P, Patel SKS, Kulshrestha S, Ratho RK, et al. Waves and variants of SARS-CoV-2: understanding the causes and effect of the COVID-19 catastrophe. Infection. 2021:1–16. [Google Scholar]
  • 6.Advies n.a.v. OMT 2019-nCoV (Wuhan): Rijksinstituut voor Volksgezondheid en Milieu (RIVM), 2020.
  • 7.Borak J. Airborne transmission of COVID-19: Oxford University Press; UK; 2020. p. 297–9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Van Doremalen N, Bushmaker T, Morris DH, et al. Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1. New England journal of medicine 2020; 382:1564–7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Nguyen LH, Drew DA, Graham MS, Joshi AD, Guo C-G, Ma W, et al. Risk of COVID-19 among front-line health-care workers and the general community: a prospective cohort study. The Lancet Public Health. 2020;5(9):e475–e83. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Magnusson K, Nygård K, Methi F, Vold L, Telle K. Occupational risk of COVID-19 in the first versus second epidemic wave in Norway, 2020. Eurosurveillance. 2021;26(40):2001875. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.den Hartog G, Vos ER, van den Hoogen LL, van Boven M, Schepp RM, Smits G, et al. Persistence of Antibodies to Severe Acute Respiratory Syndrome Coronavirus 2 in Relation to Symptoms in a Nationwide Prospective Study. Clinical Infectious Diseases. 2021;73(12):2155–62 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Kwart 15-plussers spreekt thuis dialect of andere taal dan Nederlands. Available at: https://www.cbs.nl/nl-nl/nieuws/2021/28/kwart-15-plussers-spreekt-thuis-dialect-of-andere-taal-dan-nederlands.
  • 13.Beijing Wantai Biological Pharmacy Enterprise Co. L. WANTAI SARS-CoV-2 Ab ELISA. Available at: https://www.dbaitalia.it/newsletter/sars-cov-2_ab_elisa_v1-ce_ifu.pdf. Accessed 22-7-2021.
  • 14.van den Beld MJ, Murk J-L, Kluytmans J, et al. Increasing the Efficiency of a National Laboratory Response to COVID-19: a Nationwide Multicenter Evaluation of 47 Commercial SARS-CoV-2 Immunoassays by 41 Laboratories. Journal of Clinical Microbiology 2021; 59:e00767–21. doi: 10.1128/JCM.00767-21 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Slot E, Hogema BM, Zaaijer HL. Antistoffen tegen coronavirus begin januari bij 13% van de donors. Available at: https://www.sanquin.nl/over-sanquin/nieuws/2021/01/antistoffen-tegen-coronavirus-bij-13-procent-van-de-donors-januari-2021. Accessed 20-7-2021. [Google Scholar]
  • 16.Vos ER, van Boven M, den Hartog G, Backer JA, Klinkenberg D, van Hagen CC, et al. Associations Between Measures of Social Distancing and Severe Acute Respiratory Syndrome Coronavirus 2 Seropositivity: A Nationwide Population-based Study in the Netherlands. Clinical Infectious Diseases. 2021;73(12):2318–21. doi: 10.1093/cid/ciab264 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Koh D. Occupational risks for COVID-19 infection. Occupational Medicine (Oxford, England) 2020; 70:3. doi: 10.1093/occmed/kqaa036 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Backer JA, Mollema L, Vos ER, et al. Impact of physical distancing measures against COVID-19 on contacts and mixing patterns: repeated cross-sectional surveys, the Netherlands, 2016–17, April 2020 and June 2020. Eurosurveillance 2021; 26:2000994. doi: 10.2807/1560-7917.ES.2021.26.8.2000994 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Brinkhues S, Schram MT, Hoebe CJPA, et al. Social networks in relation to self-reported symptomatic infections in individuals aged 40–75—the Maastricht study–. BMC Infectious Diseases 2018; 18:300. doi: 10.1186/s12879-018-3197-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Madsen JR, Nielsen JP, Fogh K, Hansen CB, Nielsen PB, Lange T, et al., editors. Anti-SARS-CoV-2 seropositivity among medical students in Copenhagen. Open forum infectious diseases; 2021: Oxford University Press; US. doi: 10.1093/ofid/ofab273 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Linka K, Peirlinck M, Sahli Costabal F, Kuhl E. Outbreak dynamics of COVID-19 in Europe and the effect of travel restrictions. Computer Methods in Biomechanics and Biomedical Engineering 2020; 23:710–7. doi: 10.1080/10255842.2020.1759560 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Fernandes S, Sosa-Napolskij M, Lobo G, Silva I. Impact of the COVID-19 pandemic in the Portuguese population: Consumption of alcohol, stimulant drinks, illegal substances, and pharmaceuticals. Plos one. 2021;16(11):e0260322. doi: 10.1371/journal.pone.0260322 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Rishi P, Thakur K, Vij S, Rishi L, Singh A, Kaur IP, et al. Diet, gut microbiota and COVID-19. Indian Journal of Microbiology. 2020;60(4):420–9. doi: 10.1007/s12088-020-00908-0 [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Ray Borrow

25 Mar 2022

PONE-D-22-02052Exposure factors associated with SARS-CoV-2 seroprevalence during the first eight months of the COVID-19 pandemic in the Netherlands: a cross-sectional studyPLOS ONE

Dear Dr. Pagen,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised below during the review process. Please submit your revised manuscript by May 09 2022 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Ray Borrow, Ph.D., FRCPath

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at 

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf.

2. We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. 

In your revised cover letter, please address the following prompts:

a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially identifying or sensitive patient information) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. Please see http://www.bmj.com/content/340/bmj.c181.long for guidelines on how to de-identify and prepare clinical data for publication. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories.

We will update your Data Availability statement on your behalf to reflect the information you provide.

3. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

********** 

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

********** 

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

********** 

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

********** 

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Dear author,

The paper entitled “Exposure factors associated with SARS-CoV-2 seroprevalence during the first eight months of the COVID-19 pandemic in the Netherlands: a cross-sectional study” is interesting despite some limitations. This paper should be review accord with comments below.

Abstract

The background of this paper should be rewritten to indicate the main aim of this research, because is not clear the objective of this research.

In the methods is refer a sample with 10,000 inhabitants, but the results are reported to the 10,001, is confused. The authors should to explain in the methods all inhabitants that was used to this study.

Introduction

The introduction is clear and is appropriated to this research, however may be mentioned the implications in the population provoked by COVID-19 infection, such as, lockdown in the home. Include the reference doi: 10.1371/journal.pone.0260322. in the paper.

Methods

In the online questionnaire was ask “who do you live with their”? And, if have children that go to school?

The blood samples were used only to SARS-CoV-2-ab ELISA test? Which amount of blood sample was need to proceed the ELISA test? Were done duplicates?

The samples that obtain results in the borderline, were test again? Or used other kit or technique? Why you don´t confirmed these results with the PCR assay?

Results

In the figure 2 can you explain who are reserve list participants? The profile of these participants is similar to the other participants (10,000 initial)?

Which the variables do you used to multivariate analysis?

Discussion

The online questionnaire asked about the health condition of participants? The health condition (before COVID-19) the participants is important because may be predispose the individuals to COVID-19 infection – this theme should be addressed in the discussion. The same to the cohabitation and the presence of children that go to the school.

Reviewer #2: In this paper entitled "Exposure factors associated with SARS-CoV-2 seroprevalence during the first eight months of the COVID-19 pandemic in the Netherlands," the authors investigated a wide variety of demographic, behavioral, and social exposure factors associated with seropositivity. The results indicated that 19.5 % of the participants were seropositive. The manuscript has potential but has some issues that have to be addressed for the manuscript to be published in PLOS ONE journal.

Minor comments:

1) Did the author ask about the vaccination status of the participants?

2) Introduction Section: the authors should provide information like mortality rate, incubation, various initial prevention approaches, and diet and natural biomolecules for improving immunity and health (doi: 10.1007/s12088-020-00908-0).

3) Introduction Section: Minor information on the variants of COVID-19 and their future challenges can be included i.e. doi: 10.1007/s15010-021-01734-2.

4) The authors should cross-check all abbreviations in the manuscript. Initially, define in the full name followed by abbreviation.

5) Highlight the importance of the study in the manuscript.

********** 

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: Yes: Aditya Kumar Sharma

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2022 May 12;17(5):e0268057. doi: 10.1371/journal.pone.0268057.r002

Author response to Decision Letter 0


7 Apr 2022

Dear Dr. Borrow,

Thank you for giving us the opportunity to revise our manuscript.

We also thank the reviewers for their helpful comments, which we have addressed in the revised manuscript and in our point-by-point reply below.

We hope that our comments are satisfactory and that the paper is now acceptable for publication in PLOS ONE.

Yours sincerely,

On behalf of all coauthors,

Demi Pagen

Response to the Editor:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf.

Thank you for indicating inaccuracies according to the style requirements. All style requirements are checked and adjusted according to the templates.

2. We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions.

In your revised cover letter, please address the following prompts:

a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially identifying or sensitive patient information) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. Please see http://www.bmj.com/content/340/bmj.c181.long for guidelines on how to de-identify and prepare clinical data for publication. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories.

We will update your Data Availability statement on your behalf to reflect the information you provide.

Thank you for pointing out the unacceptability of our data availability statement. There are legal restrictions on sharing data publicly, as the data of our study contain potentially identifying and sensitive participant information. Due to the General Data Protection Regulation, it is not allowed to distribute or share any personal data that can – directly or indirectly – be traced back to an individual. Besides, publicly sharing the data would not be in accordance with participants’ consent obtained for this study. Therefore, data are available from the head of the data-archiving of the Public Health Service South Limburg on reasonable request (Helen Sijstermans: helen.sijstermans@ggdzl.nl). This statement is in line with previously published articles of our research group (https://doi.org/10.1371/journal.pone.0258701).

3. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

Thank you for highlighting incorrect references included in the reference list. All references are reviewed and replaced or adjusted according to the requirements. Adjusted references in the Revised Manuscript include reference 7 (page 21 line 457), 9 (page 22 line 460-462), 10 (page 22 line 463-464), 11 (page 22 line 465-468), 16 (page 23 line 482-485), and 20 (page 23 line 494-496).

Response to reviewers:

Reviewer #1: Dear author,

The paper entitled “Exposure factors associated with SARS-CoV-2 seroprevalence during the first eight months of the COVID-19 pandemic in the Netherlands: a cross-sectional study” is interesting despite some limitations. This paper should be review accord with comments below.

Thank you for the complements. We reviewed the paper according to the comments and incorporated them into the Revised Manuscript.

Abstract

1. The background of this paper should be rewritten to indicate the main aim of this research, because is not clear the objective of this research. In the methods is refer a sample with 10,000 inhabitants, but the results are reported to the 10,001, is confused. The authors should to explain in the methods all inhabitants that was used to this study.

Thank you for pointing out indistinctness about the study aim and obtained study population. We elaborated on both points – by stating the research aim more pronounced and explaining the use of a reserve list – to enhance clarity in the Revised Manuscript; Abstract section Background (page 2 line 37-41) and section Method (page 2 line 46-49).

Introduction

2. The introduction is clear and is appropriated to this research, however may be mentioned the implications in the population provoked by COVID-19 infection, such as, lockdown in the home. Include the reference doi: 10.1371/journal.pone.0260322. in the paper.

Thank you for this suggestion, we agree that the indirect impact of the COVID-19 pandemic on general health and lifestyle cannot be denied. Therefore, we added a statement acknowledging this point including the reference in the Revised Manuscript; Discussion section (page 19 line 378-382).

Methods

3. In the online questionnaire was ask “who do you live with their”? And, if have children that go to school?

Thank you for pointing this out. In the questionnaire, we determined participants home situation by asking whether they were married/living together or single/widow. Besides, we questioned whether the participants had children (living at home/not living at home) or not. It was not further specified if the children were currently going to school.

We combined the information about their marital status and having children into one variable to get a better picture of the participant’s home situation and determined seroprevalence per situation (Table 1).

Table 1. Seroprevalence by home situation

Home situation n Seroprevalence (%)

Single/widow – no children 1,291 20.6

Single/widow – children not living at home 399 19.3

Single/widow – children living at home 336 11.6

Married/living together – no children 1,483 19.4

Married/living together – children not living at home 2,679 20.3

Married/living together – children living at home 3,813 19.3

Being single/widow and having children living at home, resulted in a significantly lower seroprevalence. However, as we were interested in investigating factors that resulted in a higher risk of being exposed – reflected by a higher seroprevalence compared to the average of 19.5% in the overall population - we did not take home situation into account in further analysis, due to the fact that it did not contribute to a higher exposure risk.

4. The blood samples were used only to SARS-CoV-2-ab ELISA test? Which amount of blood sample was need to proceed the ELISA test? Were done duplicates?

The blood samples (one 10 ml EDTA tube per participant) were only collected to perform the SARS-CoV-2 Ab ELISA antibody test. This test was used as it showed the best performance in a multicenter evaluation by the National Institute for Health and Environment. A minimum of 100 μl serum per well was needed to perform the Wantai ELISA. Each sample was tested once, as our validation showed the variance of duplicates within one run to be between 1.7-2.4%. Therefore, we determined that testing each sample once was sufficient.

5. The samples that obtain results in the borderline, were test again? Or used other kit or technique? Why you don´t confirmed these results with the PCR assay?

Thank you for this suggestion. Borderline values were not tested again. Based on pilot experience using the Wantai among five hospital employee with serum pairs, four out of five became positive. Therefore, we decided to classify the borderline values as positives. Due to the small number of borderline values, an overestimation of the seroprevalence seemed negligible.

PCR testing probably would not have resulted in an exclusive answer, as PCR testing is only capable of indicating a current infection, and participants could have been infected up to eight months before the blood drawing and antibody testing was performed. It is acceptable to assume that participants with borderline results had been infected several months before, probably reflecting declining antibody levels, as sero-reconversion occurs over time. Due to this, we did not consider PCR testing as an alternative to indicate whether participants with borderline values had (previously) been infected.

Results

6. In the figure 2 can you explain who are reserve list participants? The profile of these participants is similar to the other participants (10,000 initial)?

Thank you for this suggestion, we appreciate that you indicate unclarity about the inclusion of the reserve participants. The first 10,000 registrations were determined to be the initial registrations. The registration link automatically allocated registrations beyond the first 10,000 to the reserve list (maximum capacity of 3,000 registrations). In order to assure sufficient participants (minimally 10,000) with complete participation (both questionnaire and blood drawing; antibody testing), reserve participants were invited to participate when initial registered participants declined participation. The resevres were invited on first-come-first-serve base, so no selection was made according to demographic factors. This is clarified in the Revised Manuscript; Abstract section Method (page 2 line 46-49) and Method section subheading Participants (page 5 line 134-137).

Despite we did not take demographic factors into account when inviting reserve participants, here we describe the demographic factors of the initial and reserve list participants, showing a comparable age and sex distribution between initial and reserve list registrations (Table 2).

Table 2. Age and sex distribution of initial, reserve list and overall participants

Initial (n=9,252) Reserve list (n=749) Participants (n=10,001)

Sex, n(%)

Women 5,380 (58.1) 449 (59.9) 5,829 (58.3)

Men 3,870 (41.8) 297 (39.7) 4,167 (41.7)

Other 2 (0.1) 3 (0.4) 5 (0)

Age, mean (SD) 50 (15) 48 (15) 49 (15)

Age, n(%)

18-29 1,106 (12.0) 102 (13.6) 1,208 (12.1)

30-39 1,547 (16.7) 129 (17.2) 1,676 (16.8)

40-49 1,626 (17.6) 140 (18.7) 1,766 (17.7)

50-59 2,218 (24.0) 175 (23.4) 2,393 (23.9)

60-69 2,018 (21.8) 145 (19.4) 2,163 (21.6)

70-79 695 (7.5) 51 (6.8) 746 (7.5)

80+ 42 (0.5) 7 (0.9) 49 (0.5)

7. Which the variables do you used to multivariate analysis?

All investigated exposure factors statistical significantly (p<0.05) associated with seropositivity in univariate analyses (indicating a higher risk of exposure) and general confounders (age and sex) were maintained in the multivariate model. These included: sex, age, level of education, geographical region, working from home per work sector, currently following education, being member of multiple associations/clubs, travelled for winter sports to Austria and visited an après-ski bar, travelled to Spain, celebrated carnival, attended or participated in singing activities, attended a funeral, played a wind instrument in interplay, visited a sport event, practiced gymnastics, practiced a balls sport, visited a bar or café, visited a club or disco, went out for dinner, and took a day trip with bus or boat. The selection procedure of variables to be maintained in the multivariable model is described in the Manuscript; Method section subheading Statistical analysis (page 8 line 205-209).

Discussion

8. The online questionnaire asked about the health condition of participants? The health condition (before COVID-19) the participants is important because may be predispose the individuals to COVID-19 infection – this theme should be addressed in the discussion. The same to the cohabitation and the presence of children that go to the school.

Thank you for these suggestions. We recognize the importance about general health in relation to COVID-19 predisposition. The questionnaire included one question on the subjective assessment of the participants general health: ‘’In general, I think my health is: excellent, very good, good, moderate, or bad’’. However, as the exact moment of infection was generally not known, it cannot be excluded that the general health status was already affected by the previous infection in our study. Therefore, correcting for general health before the infection was challenging. However, while keeping the previously mentioned limitation into account, we investigated whether serostatus differed according to general health status, which resulted in no significant differences (Chi-square=6.458 p=0.167; excellent n=1,286 SP=20.6%, very good n=3,251 SP=20.3%, good n=4,517 SP=19.1%, moderate n=878 SP=17.0% and bad n=69 SP=17.4%). Therefore, general health score was not included in further analysis. Furthermore, general health before the COVID-19 pandemic was not asked, so unfortunately we were not able to include this in our analysis.

We included a statement on the importance of general health and home situation (having children going to school) in the Revised Manuscript; Discussion section (page 20 line 416-418).

Reviewer #2: In this paper entitled "Exposure factors associated with SARS-CoV-2 seroprevalence during the first eight months of the COVID-19 pandemic in the Netherlands," the authors investigated a wide variety of demographic, behavioral, and social exposure factors associated with seropositivity. The results indicated that 19.5 % of the participants were seropositive. The manuscript has potential but has some issues that have to be addressed for the manuscript to be published in PLOS ONE journal.

Thank you for your compliments. We addressed the issues you pointed out in our Revised Manuscript.

Minor comments:

1) Did the author ask about the vaccination status of the participants?

Thank you for this suggestion. The study was conducted at the end of 2020 (November – December), before vaccination started in the Netherlands. Therefore, the questionnaire did not include any questions on previous COVID-19 vaccination, as this was not relevant at that time.

2) Introduction Section: the authors should provide information like mortality rate, incubation, various initial prevention approaches, and diet and natural biomolecules for improving immunity and health (doi: 10.1007/s12088-020-00908-0).

Thank for your suggestion to include information on diet in relation to improving immunity and health. We included and statement about the importance of a balanced diet in relation to health and the reference in the Revised Manuscript; Discussion section (page 19 line 382-384).

3) Introduction Section: Minor information on the variants of COVID-19 and their future challenges can be included i.e. doi: 10.1007/s15010-021-01734-2.

Thank you for your suggestion to incorporate information about virus variants. We included this and the reference in the Revised Manuscript; Introduction section (page 3 line 77-80).

4) The authors should cross-check all abbreviations in the manuscript. Initially, define in the full name followed by abbreviation.

Thank you for indicating overlooked errors in the use of abbreviations. We corrected the following abbreviations in the Revised Manuscript;

Introduction section (page 3 line 69):

- coronavirus disease (COVID-19) adjusted into coronavirus disease 2019 (COVID-19)

Method section subheading Data collection (page 6 line 148-149 and 152-153):

- EDTA adjusted into ethylenediaminetetraacetic acid (EDTA)

- ELISA adjusted into enzyme-linked immunoassay (ELISA)

Method section subheading Statistical analysis (page 9 line 213):

- SPSS adjusted into Statistical Package for the Social Sciences (SPSS)

Results section subheading Seroprevalence (page 12 line 247):

- CI adjusted into Confidence Interval (CI)

Results section subheading Exposure factors associated with seropositivity (page 12 line 257):

- OR adjusted into Odds Ratio (OR)

5) Highlight the importance of the study in the manuscript.

Thank you for your suggestion to highlight the importance of our study. We emphasized the importance multiple times in the Revised Manuscript; Introduction section (page 4 line 78-80 and 5 line 111-114) Discussion section (page 20 line 429-431).

Attachment

Submitted filename: Response to Reviewers.docx

Decision Letter 1

Ray Borrow

22 Apr 2022

Exposure factors associated with SARS-CoV-2 seroprevalence during the first eight months of the COVID-19 pandemic in the Netherlands: a cross-sectional study

PONE-D-22-02052R1

Dear Dr. Pagen,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Ray Borrow, Ph.D., FRCPath

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Acceptance letter

Ray Borrow

4 May 2022

PONE-D-22-02052R1

Exposure factors associated with SARS-CoV-2 seroprevalence during the first eight months of the COVID-19 pandemic in the Netherlands: a cross-sectional study

Dear Dr. Pagen:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Prof. Ray Borrow

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    Attachment

    Submitted filename: Response to Reviewers.docx

    Data Availability Statement

    Data cannot be shared publicly because the data contains potentially identifying and sensitive participant information. Due to the General Data Protection Regulation, it is not allowed to distribute or share any personal data that can – directly or indirectly – be traced back to an individual. Besides, publicly sharing the data would not be in accordance with participants’ consent obtained for this study. Therefore, data are available from the head of the data-archiving of the Public Health Service South Limburg on reasonable request (Helen Sijstermans: helen.sijstermans@ggdzl.nl).


    Articles from PLoS ONE are provided here courtesy of PLOS

    RESOURCES